Literature DB >> 9291346

Association of recurrent vaginal candidiasis and secretory ABO and Lewis phenotype.

W Chaim1, B Foxman, J D Sobel.   

Abstract

The relationship between ABO-Le secretor phenotype and susceptibility to recurrent idiopathic vulvovaginal candidiasis (RVVC) was investigated. ABO and Lewis blood typing was done for 38 women with RVVC (case-patients) and for women in 2 control groups, consisting of 58 healthy women, who were friends identified by case-patients, and 38 race-matched, healthy hospital employees. The 3 groups were similar with regard to age and race. There was no difference in the distribution of ABO phenotype between case-patients and controls. Case-patients were more likely than members of either control group to have Le(a+ b-) (nonsecretor) rather than Le(a- b+) (secretor) blood type. With combined nonsecretor Le(a+ b-) phenotype and absence of the Lewis gene Le(a- b-), the relative risk of chronic recurring vulvovaginal candidiasis was 2.41-4.39, depending on the analysis technique and control group. In conclusion, there is an increased frequency of ABO-Le nonsecretor status among women with RVVC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9291346     DOI: 10.1086/517314

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Vulvar Vestibulitis Syndrome: A Post-infectious Entity?

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-12       Impact factor: 3.725

2.  Increased susceptibility of secretor factor gene Fut2-null mice to experimental vaginal candidiasis.

Authors:  Elizabeth A Hurd; Steven E Domino
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

Review 3.  Anticandidal immunity and vaginitis: novel opportunities for immune intervention.

Authors:  Antonio Cassone; Flavia De Bernardis; Giorgio Santoni
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

4.  Genetic basis for recurrent vulvo-vaginal candidiasis.

Authors:  Martin Jaeger; Theo S Plantinga; Leo A B Joosten; Bart-Jan Kullberg; Mihai G Netea
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

5.  Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013).

Authors:  W Mendling; K Friese; I Mylonas; E-R Weissenbacher; J Brasch; M Schaller; P Mayser; I Effendy; G Ginter-Hanselmayer; H Hof; O Cornely; M Ruhnke
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-04       Impact factor: 2.915

Review 6.  Candida infections of the genitourinary tract.

Authors:  Jacqueline M Achkar; Bettina C Fries
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

7.  Pathogenesis of Recurrent Vulvovaginal Candidiasis.

Authors:  Jack D. Sobel
Journal:  Curr Infect Dis Rep       Date:  2002-12       Impact factor: 3.725

8.  An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis.

Authors:  Paul L Fidel; Melissa Barousse; Terri Espinosa; Mercedes Ficarra; Joy Sturtevant; David H Martin; Alison J Quayle; Kathleen Dunlap
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

9.  LacZ expression in Fut2-LacZ reporter mice reveals estrogen-regulated endocervical glandular expression during estrous cycle, hormone replacement, and pregnancy.

Authors:  Steven E Domino; Elizabeth A Hurd
Journal:  Glycobiology       Date:  2003-10-23       Impact factor: 4.313

10.  Cervical mucins carry alpha(1,2)fucosylated glycans that partly protect from experimental vaginal candidiasis.

Authors:  Steven E Domino; Elizabeth A Hurd; Kristina A Thomsson; David M Karnak; Jessica M Holmén Larsson; Elisabeth Thomsson; Malin Bäckström; Gunnar C Hansson
Journal:  Glycoconj J       Date:  2009-12       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.